Innvierte allocates in March more than 113 million euros to 6 new co-investments in risk capital and 2 investment vehicles
Since January 2026, the CDTI Innovation, through Innvierte, has closed co-investment operations in 20 companies with a commitment of 53.37 million euros and has committed investments in 4 investment vehicles with a commitment of 141.6 million euros
The CDTI Innovation, promoter and sole shareholder of the company Innvierte, closed, last March, 6 co-investment operations, 2 of them strategic, amounting to 33,063,000 euros, in particular:
BIOHERENT, S.L. (Málaga) is a company that develops in vitro diagnostic systems based on photonic biosensors for the detection of allergies to medicines, including antibiotics and critical drugs used in anesthesia and in biological therapies. The investment is made with BULLNET CAPITAL III, SCR SME S.A. and ACE 53, SLU and the contribution of the CDTI Innovation is 284,000 euros.
MOA BIOTECH, SL. (MOA Foodtech) (Navarra) redefines the agri-food industry by developing ingredients with AI and fermentation based on the revaluation of agri-food by-products. Its business model is twofold: it offers a portfolio of its own functional ingredients and facilitates the co-development of new products together with industrial partners. The investment is made with Swanlaab Innvierte Agrifood Tech, FCR and the contribution of the CDTI Innovation is 674,000 euros.
TELUM THERAPEUTICS, S.L. (Navarra) es una empresa que desarrolla proteínas sintéticas para luchar contra cepas bacterianas multirresistentes. The investment is made with INVIVO VENTURES, FCR, NAVARRA TECH TRANSFER FCR and UN R+D+I TECHNOLOGY TRANSFER FCR and the contribution of the CDTI Innovation is 216,000 euros.
ZOUNDREAM, S.L. (Barcelona) is a company that uses artificial intelligence (AI) and advanced voice recognition technology to analyze and interpret the crying of newborns, with the aim of monitoring the baby by identifying his needs. At the same time, it is developing acoustic biomarkers for the monitoring of neurodevelopment associated with vocal maturation, which allows to support the early identification of warning signals associated with neurodevelopment disorders, such as autism or language delays. The investment is made together with CRB DIGITAL HEALTH III, F.C.R.E. and CRB DIGITAL HEALTH III BIS F.C.R.E., S.A. and the contribution of the CDTI Innovation is 675,000 euros.
In addition, in the line of strategic companies, CDTI Innovation has committed 24.3 million euros in the company ONCOMATRYX BIOPHARMA, S.A. (Vizcaya), to reinforce the development of new oncological therapies and advance in the implementation of a manufacturing plant Fill & Finish specialized in high-power drugs; and 6.8 million euros in the company XOOPLE, S.L. (Madrid), the data infrastructure company that is building a global system for recording physical changes on Earth.
Since January 2026, the CDTI Innovation, through Innvierte, has closed co-investment operations in 20 companies with a commitment of 53.37 million euros and has committed investments in 4 investment vehicles with a commitment of 141.6 million euros.
Investment vehicles
In addition, last March, the CDTI Innovation, through Innvierte, has committed investments in two investment vehicles in the amount of 80.56 million euros. In particular:
- CRB Digital Health III, F.C.R.E. is the first European fund 100% dedicated to digital health based in Spain. It is managed by CRB Health Tech, S.G.E.I.C., S.A. (with offices in Madrid and Barcelona) and is focused on investing in companies with a proven model and a clear opportunity for growth. Its strategy is oriented to the development of disruptive technologies applied to the prevention, diagnosis and treatment of patients, as well as platforms that contribute to improve the efficiency and sustainability of the healthcare system. The commitment of the CDTI Innovation, through Innvierte, is 10 million euros.
- INCEPTIONBIO INNVIERTE, FCRE es un fondo gestionado por YSIOS CAPITAL PARTNERS, S.G.E.I.C., S.A.U. (San Sebastián/Barcelona), which is launched to promote the creation of biotechnology companies and the development of technology transfer projects in early stages, with special focus on Spain. The commitment of the CDTI Innovation, through Innvierte, is up to 70.56 million euros.
Innvierte
Innvierte is an initiative whose objective is to promote business innovation by supporting venture capital investment in technology-based or innovative companies. This program is implemented through the closed-ended collective investment company Innvierte Economía Permanente SICC S.M.E., S.A., self-managed and subject to the supervision of the National Securities Market Commission and of which CDTI Innovation is a single shareholder.
To date, the CDTI Innovation has committed, through Innvierte, 3,478.5 M€ in 61 investment vehicles and, through its co-investment line, has directly committed an amount of 866.1 M€ in 197 companies.
Innvierte is part of the Spanish Strategy of Science, Technology and Innovation 2021-2027, approved by Agreement of the Council of Ministers, in September 2020. This Strategy contains the objectives, reforms and measures that must be adopted throughout the field of R+D+I in order to boost its growth and impact, and is one of the pillars on which the design of the Government's R+D+I policy for the coming years is based.
CDTI Innovation
The Center for Technological Development and Innovation, CDTI E.P.E. It is the innovation agency of the Ministry of Science, Innovation and Universities, whose objective is the promotion of technological innovation in the business environment. The mission of the CDTI is to ensure that the Spanish business fabric generates and transforms scientific and technical knowledge into globally competitive, sustainable and inclusive growth. In 2025, within the framework of the Strategic Plan 2024-2027, the CDTI provided more than 2 billion euros of support to Spanish companies and startups.
You can check the conditions of the CDTI Innovation grants on the website: www.cdti.es.
More information:
Press Office
press@cdti.es
91-581.55.00
On the Internet
Website: www.cdti.es
On LinkedIn: https://www.linkedin.com/company/cdti/
In X: https://twitter.com/CDTI_innovacion
On YouTube: https://www.youtube.com/user/CDTIoficial
Website: https://www.innvierte.es/
This content is copyright © 2026 CDTI,EPE. The use and reproduction is allowed by citing the source and digital identity of CDTI (@CDTI_innovacion).